Core Insights - Zenas BioPharma, Inc. (NASDAQ: ZBIO) is a clinical-stage global biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs [1] - Citigroup maintains a "Buy" rating for ZBIO, indicating confidence in the company's future performance [1][5] Stock Options and Employee Incentives - Zenas BioPharma granted non-qualified stock options covering 300,000 shares to two new employees, with an exercise price of $32.59 per share [2] - The stock options have a ten-year term and will vest over four years, with 25% vesting after one year [3] - This strategy aims to retain talent and align employee interests with company performance [3] Stock Performance and Market Activity - ZBIO's stock price has increased by 3.08%, reaching $36.15, reflecting positive market sentiment [3][5] - The stock has shown significant volatility, with a daily trading range between $35.25 and $37.97 [4] - Over the past year, the stock fluctuated from a low of $5.83 to a high of $41.50, with a current market capitalization of approximately $1.51 billion [4]